Endocrinology · Phase 3
Tesamorelin: visceral fat in HIV
What was tested?
Tesamorelin versus placebo in people with HIV-associated abdominal fat accumulation. ↗
Registered primary question: Visceral adipose tissue; the retrieved primary-outcome field does not specify a time frame. ↗
What the reviewed report found
Journal year 2007 · Article summary reviewed 2026-08-19
Visceral adipose tissue reportedly decreased by 15.2% with tesamorelin and increased by 5.0% with placebo. More participants receiving tesamorelin withdrew because of an adverse event, while the groups did not differ significantly in the reported glycemic measures.↗
Keep in context: The publication reports a 26-week comparison using imaging of abdominal fat. That result is not a cardiovascular-outcome trial or a general-obesity result. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 412 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years to 65 Years
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2013-11-27; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Twenty-six-week visceral-fat trial
- Design in the report
- A randomized, placebo-controlled trial assessed computed-tomography visceral adipose tissue and metabolic measures over 26 weeks.↗
- Participants in the report
- The trial randomized 412 adults living with HIV who had abdominal fat accumulation during antiretroviral therapy; 86% were men.↗
- Limitations
- The 26-week trial was limited to adults living with HIV and treatment-associated abdominal fat accumulation and did not establish longer-term clinical outcomes.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
TH9507 in Patients With HIV-Associated Lipodystrophy ↗
Protocol identifier: TH9507/III/LIPO/010. Sponsor: Theratechnologies.
Retrieved 2026-09-20; SHA-256 cb0e4d9209873e96e5201e42be36d3a75d79295f21afeb36ec26b307790764d2.
PMID 18057338
Metabolic effects of a growth hormone-releasing factor in patients with HIV ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 18057338. SHA-256 b9b2737876819a52052ecd9dc7208be1ad5712f7a133c5c13d04f6663f02d118.
Scientific summary uses the original 2026-08-19 source snapshot: SHA-256 3e4af3676d797f96af2feabb38705dd17e6e1c1d9011cd116c22b449fb27151c.